To evaluate the effect of preoperative intravitreal injection of bevacizumab on surgery and on the early postoperative course in diabetic patients undergoing vitrectomy for dense vitreous hemorrhage.
Thirty-five patients with dense diabetic vitreous hemorrhage were randomly assigned to a group that received 1.25 mg of intravitreal bevacizumab 1 week before vitrectomy (18 patients) or the control group (17 patients). To compare the complexity of two groups, intraoperative complexity score and proliferative diabetic vitreoretinopathy stage were recorded. Intraoperative bleeding, break formation, number of endodiathermy applications, best-corrected visual acuity, anatomical outcome at Month 3 and at final follow-up, and postoperative complications were evaluated.
Mean complexity scores and proliferative diabetic vitreoretinopathy stages of both groups were similar. The mean score of bleeding was 1.05 in the injection group versus 1.76 in the control group (P = 0.35); endodiathermy applications and break formations were 0.44 versus 0.52 (P = 0.68) and 0.22 versus 0.29 (P = 0.60) in the injection and control groups, respectively. Anatomical outcome and visual acuity at Month 3 and at the final follow-up were similar.
The results suggest that intravitreal injection of bevacizumab before vitrectomy for dense diabetic vitreous hemorrhage has no significant effect on facilitation of surgery or on the early postoperative course.
Thirty-five patients with dense diabetic vitreous hemorrhage were randomly assigned to treatment with 1.25 mg of intravitreal bevacizumab 1 week before vitrectomy or the control group. This procedure does not seem to facilitate surgery or affect the early postoperative course in these patients.
From the Eye Research Center, Farabi Eye Hospital, Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran.
The study is the fellowship thesis of Dr. A. R. Majidi.
The authors have no financial or conflicts of interest in any material or equipment used in the study.
Reprint requests: Ali Reza Majidi, MD, Department of Ophthalmology, Tehran University of Medical Sciences, Eye Research Center, Farabi Eye Hospital, Qazvin Square, Tehran 1336616351, Iran; e-mail: firstname.lastname@example.org